In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 121 to 130 of 303

TitleTypeExpected publication date
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Technology appraisal guidance
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459Technology appraisal guidanceTBC
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Iptacopan for treating complement 3 glomerulopathy ID6283Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All